{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:56:20Z","timestamp":1792410980103,"version":"4.4.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Programmed cell death 1 (PD-1) inhibitors have been the standard first-line treatment for advanced melanoma; however, their clinical benefit in advanced melanoma predominantly of acral subtype remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of toripalimab (a PD-1 inhibitor) vs dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This multicenter, open-label, positive-control phase 3 randomized clinical trial enrolled patients with advanced melanoma from January 22, 2018, to July 12, 2023. Eligible patients had histologically confirmed stage III or IV melanoma and no prior systemic therapy for advanced melanoma. Data were analyzed from September 23 to November 27, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>\n                      Patients were randomized (1:1) to receive toripalimab, 240 mg, every 2 weeks for up to 2 years, or dacarbazine, 1000 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , every 3 weeks until disease progression or intolerable toxic effects. Patients in the dacarbazine group were allowed to receive toripalimab after radiographic disease progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Progression-free survival (PFS) assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors, version 1.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The analysis included 256 patients (median [range] age, 58 [18-85] years; 113 females [44.3%] and 142 males [55.7%]), among whom 160 participants (62.7%) had acral melanoma; 127 were randomized to receive toripalimab and 128 to dacarbazine (1 patient was excluded for Good Clinical Practice violation). The median (range) follow-up period was 11.8 (0.1-62.5) months. Toripalimab significantly reduced the risk of disease progression or death by 29.2% (hazard ratio, 0.71; 95% CI, 0.53-0.95;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.02) compared with dacarbazine as assessed by BICR . Consistent PFS benefit was observed in most predefined subgroups, including patients with acral subtype. The BICR-assessed objective response rate of 11.0% (95% CI, 6.2%-17.8%) vs 8.6% (95% CI, 4.4%-14.9%), and the median  duration of response of 13.8 (95% CI, 5.9-not evaluable) months vs 6.9 (95% CI, 3.8-not evaluable) months, respectively, also favored toripalimab over dacarbazine. Grade 3 or worse treatment-related adverse events occurred in 36 patients (28.3%) receiving toripalimab, with the most common (\u22653%) being increased lipase (11 patients [8.7%]), anemia (5 patients [3.9%]), increased \u03b3-glutamyltransferase (4 patients [3.1%]), hyponatremia (4 patients [3.1%]), and increased blood triglycerides (4 patients [3.1%]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This phase 3 randomized clinical trial found that as a first-line treatment for advanced melanoma predominantly of acral subtype, toripalimab showed a significant PFS benefit over dacarbazine and an acceptable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03430297\">NCT03430297<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.5751","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T16:30:56Z","timestamp":1767371456000},"page":"243","source":"Crossref","is-referenced-by-count":9,"title":["Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype"],"prefix":"10.1001","volume":"12","author":[{"given":"Xinan","family":"Sheng","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue, Hunan Cancer Hospital, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Rare and Head and Neck Oncology, Zhejiang Cancer Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Biotherapy Center, Yunnan Cancer Hospital, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Tumor Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Melanoma, Urologic, and Soft Tissue Oncology, Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First People\u2019s Hospital of Hefei, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanli","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department II of Thoracic Medicine, Hunan Cancer Hospital, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Shanghai Junshi Biosciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junliang","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Junshi Biosciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Yu","sequence":"additional","affiliation":[{"name":"Shanghai Junshi Biosciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[{"name":"Shanghai Junshi Biosciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hao","sequence":"additional","affiliation":[{"name":"Shanghai Junshi Biosciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Jin","sequence":"additional","affiliation":[{"name":"Shanghai Junshi Biosciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zou","sequence":"additional","affiliation":[{"name":"Shanghai Junshi Biosciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"coi250079r1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040.","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"coi250079r2","first-page":"63","article-title":"Epidemiology of Melanoma.","volume":"9","author":"Saginala","year":"2021","journal-title":"Med Sci (Basel)"},{"issue":"3","key":"coi250079r3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"coi250079r4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022.","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"issue":"4","key":"coi250079r5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch Dermatol"},{"key":"coi250079r6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"key":"coi250079r7","doi-asserted-by":"publisher","first-page":"31432","DOI":"10.1038\/srep31432","article-title":"Acral melanoma in Chinese: a clinicopathological and prognostic study of 142 cases.","volume":"6","author":"Lv","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"coi250079r8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/path.5213","article-title":"Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities.","volume":"247","author":"Rabbie","year":"2019","journal-title":"J Pathol"},{"issue":"3","key":"coi250079r9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/jso.27953","article-title":"A review of melanoma subtypes: genetic and treatment considerations.","volume":"131","author":"Druskovich","year":"2025","journal-title":"J Surg Oncol"},{"issue":"16","key":"coi250079r10","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.3390\/cancers15164176","article-title":"Immunotherapy in melanoma: recent advancements and future directions.","volume":"15","author":"Mooradian","year":"2023","journal-title":"Cancers (Basel)"},{"key":"coi250079r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104276","article-title":"The treatment of advanced melanoma: current approaches and new challenges.","volume":"196","author":"Boutros","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"coi250079r12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial.","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol"},{"issue":"26","key":"coi250079r13","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"coi250079r14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"coi250079r15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"coi250079r16","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151).","volume":"12","author":"Si","year":"2019","journal-title":"Transl Oncol"},{"issue":"1","key":"coi250079r17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-018-0693-2","article-title":"Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.","volume":"12","author":"Tang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"8","key":"coi250079r18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/14712598.2020.1762561","article-title":"Toripalimab for the treatment of melanoma.","volume":"20","author":"Tang","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"coi250079r19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12885-022-10473-y","article-title":"Safety and efficacy of pucotenlimab (HX008) in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.","volume":"23","author":"Cui","year":"2023","journal-title":"BMC Cancer"},{"issue":"21","key":"coi250079r20","first-page":"322","article-title":"Chinese guidelines on the diagnosis and treatment of melanoma (2015 edition).","volume":"3","author":"Guo","year":"2015","journal-title":"Ann Transl Med"},{"issue":"4","key":"coi250079r21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"coi250079r22","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"coi250079r23","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation.","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"9839","key":"coi250079r24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"coi250079r25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2019.10.033","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.","volume":"125","author":"Hauschild","year":"2020","journal-title":"Eur J Cancer"},{"issue":"11","key":"coi250079r26","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1093\/annonc\/mdv324","article-title":"A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-na\u00efve patients with metastatic melanoma.","volume":"26","author":"Hersh","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"coi250079r27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi250079r28","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2013.79","article-title":"A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.","volume":"21","author":"Cui","year":"2013","journal-title":"Mol Ther"},{"issue":"16","key":"coi250079r29","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial.","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"coi250079r30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"coi250079r31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12967-022-03532-2","article-title":"Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma.","volume":"20","author":"Gui","year":"2022","journal-title":"J Transl Med"},{"issue":"7","key":"coi250079r33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004668","article-title":"Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.","volume":"10","author":"Bhave","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"33","key":"coi250079r34","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1200\/JCO.24.01125","article-title":"First-line nivolumab plus relatlimab versus nivolumab plus ipilimumab in advanced melanoma: an indirect treatment comparison using RELATIVITY-047 and CheckMate 067 trial data.","volume":"42","author":"Long","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi250079r35","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaoncol.2023.1363","article-title":"Camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma: the CAP 03 phase 2 nonrandomized clinical trial.","volume":"9","author":"Mao","year":"2023","journal-title":"JAMA Oncol"},{"key":"coi250079r36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2022.12.027","article-title":"Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial.","volume":"182","author":"Wang","year":"2023","journal-title":"Eur J Cancer"},{"issue":"2","key":"coi250079r37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"issue":"2","key":"coi250079r38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"coi250079r39","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1078-0432.CCR-21-2210","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma.","volume":"28","author":"Sheng","year":"2022","journal-title":"Clin Cancer Res"},{"key":"coi250079r32","unstructured":"Merck Sharp & Dohme. Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902\/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003\/E7080-G000-312\/LEAP-003)-China Extension Study. ClinicalTrials.gov identifier: NCT04889118. Accessed December 1, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04889118"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2843206\/jamaoncology_sheng_2026_oi_250079_1773666446.28319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:00:32Z","timestamp":1773932432000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2843206"}},"subtitle":["The Phase 3 MELATORCH Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.5751","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}